New data on galcanezumab show significant reduction in number of migraine headache days

Positive results from three Phase III studies of galcanezumab, an investigational treatment for the prevention of episodic and chronic migraine, will be presented today at the American Headache Society (AHS) annual scientific meeting Boston, in said US pharma major Eli Lilly (NYSE: LLY).

"The detailed Phase III results presented today represent a crucial step forward for the millions of patients living with migraine who have not yet tried, or found, an effective preventive therapy," said Christi Shaw, president of Lilly Bio-Medicines. "Following more than 25 years of research in migraine, Lilly is excited to help usher in a new era of preventive migraine therapies that may substantially improve the current standard of care for people living with migraine."

The observed safety and tolerability profile was consistent with findings from previous studies of galcanezumab. In these three studies, the most commonly-reported adverse events were injection site reactions.